Clinical Trial Update: To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the efficacy and safety of combining Anlotinib with Furmonertinib Mesylate in lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Furmonertinib Mesylate (Furmonertinib)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED